

August 29, 2018
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Launch of new Anti-CD20 Antibodies
that can be used in combination with the anti-cancer agent TREAKISYM®**

TOKYO, Japan, August 29, 2018 -- Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo) and Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto) announced today that GAZYVA® (non-proprietary name: obinutuzumab) anti-CD20 antibodies^(*) has been listed and launched in combination with the anti-cancer agent TREAKISYM® as a therapeutic option for CD20 positive follicular lymphoma.

<https://www.chugai-pharm.co.jp/english/news/detail/20180829150001.html>

Symbio Pharmaceuticals Limited (Headquarters: Tokyo, Japan; hereinafter referred to as "Symbio") obtained approval for a partial change to its marketing authorization for the anti-cancer agent TREAKISYM® (non-proprietary name: bendamustine hydrochloride) on July 2, 2018. The launch of GAZYVA® enables the combined use of TREAKISYM® and GAZYVA® for the treatment of CD20 positive follicular lymphoma, a typical histologic type of low-grade NHL, providing an additional treatment option to patients as an alternative to conventional rituximab (BR therapy).

TREAKISYM® has been newly included as a standard-of-care option for low-grade B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018 issued by JSH (Japan Society of Hematology) on July 20, 2018.

Symbio is conducting Phase 3 clinical study of TREAKISYM® in relapsed refractory diffuse large B-cell lymphoma and shall continue to develop its business to enhance corporate value by further strengthening the position of TREAKISYM® as a standard therapy for the treatment of malignant lymphoma.

(*) CD20 is a transmembrane phosphoprotein that is a surface-membrane molecule specifically expressed on lymphocyte B cells. Anti-CD20 antibodies recognize and bind to CD20 in vivo, thereby targeting B cells for destruction by natural killer cells.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for manufacturing and marketing in Japan in September 2016.
- TREAKISYM® was approved for the additional indication of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- TREAKISYM® is currently under Phase 3 clinical study for indication of diffuse large B-cell lymphoma and accumulating cases.

TREAKISYM® has been marketed by Symbio through its partnership with Eisai Co., Ltd. since December 2010.

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016 Symbio incorporated its wholly-owned subsidiary in the U.S., called Symbio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). Symbio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.